1.63
0.29 (21.64%)
| Penutupan Terdahulu | 1.34 |
| Buka | 1.37 |
| Jumlah Dagangan | 35,935,499 |
| Purata Dagangan (3B) | 12,870,252 |
| Modal Pasaran | 1,045,679,168 |
| Harga / Jualan (P/S) | 4.56 |
| Harga / Buku (P/B) | 3.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | -119.54% |
| Margin Operasi (TTM) | -42.18% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12,927.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 45.40% |
| Nisbah Semasa (MRQ) | 7.86 |
| Aliran Tunai Operasi (OCF TTM) | -204.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -142.38 M |
| Pulangan Atas Aset (ROA TTM) | -16.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Geron Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.09% |
| % Dimiliki oleh Institusi | 81.26% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |